Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo

Journal of Ethnopharmacology

Volumn 131, Issue 2, 2010, Pages 433-442

  Doo, Ah Reum ^a   Kim, Seung Nam ^a   Park, Ji Yeon ^a   Cho, Ki Ho ^a   Hong, Jongki ^a   Eun Kyung, Kim ^a   Moon, Sang Kwan ^a   Jung, Woo Sang ^a   Lee, Hyejung ^a   Jung, Jae Han ^a   Park, Hi Joon ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Apoptosis; Neuroprotection; Parkinson's disease; PI3K Akt; Yi Gan San

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTIPARKINSON AGENT; CASPASE 3; DECURSIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT EXTRACT; PROTEIN KINASE B; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; YI GAN SAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ROTAROD TEST; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANGIOSPERMS; ANIMALS; CASPASE 3; CELL LINE, TUMOR; CHROMONES; CYTOTOXINS; DISEASE MODELS, ANIMAL; DOPAMINE; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; MOTOR ACTIVITY; NEUROBLASTOMA; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHOSPHORYLATION; PHYTOTHERAPY; PROTO-ONCOGENE PROTEINS C-AKT;

PARKINSONIA;

EID: 77956266559     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.07.008     Document Type: Article

References (50)

1. + induced oxygen radical formation with mitochondrial enzymes. Free Radical Biology & Medicine 1993, 15:181-186.
2. Ballard C., Holmes C., McKeith I., Neill D., O'Brien J., Cairns N., Lantos P., Perry E., Ince P., Perry R. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. American Journal of Psychiatry 1999, 156:1039-1045.
3. Bhattacharya I., Ullrich A. Endothelin-1 inhibits adipogenesis: role of phosphorylation of Akt and ERK1/2. FEBS Letters 2006, 580:5765-5771.
4. Bloem B.R., Irwin I., Buruma O.J., Haan J., Roos R.A., Tetrud J.W., Langston J.W. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. Journal of the Neurological Sciences 1990, 97:273-293.
5. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Frontiers in Neuroendocrinology 2009, 30:142-157.
6. Cheatham B., Vlahos C.J., Cheatham L., Wang L., Blenis J., Kahn C.R. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Molecular and Cellular Biology 1994, 14:4902-4911.
7. Chung V., Liu L., Bian Z., Zhao Z., Leuk Fong W., Kum W.F., Gao J., Li M. Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: a systematic review. Movement Disorders 2006, 21:1709-1715.
8. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
9. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. Journal of Neurochemistry 2000, 74:2213-2216.
10. Deregibus M.C., Cantaluppi V., Doublier S., Brizzi M.F., Deambrosis I., Albini A., Camussi G. HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells. Journal of Biological Chemistry 2002, 277:25195-25202.
11. Dos Santos-Neto L.L., de Vilhena Toledo M.A., Medeiros-Souza P., de Souza G.A. The use of herbal medicine in Alzheimer's disease-a systematic review. Evidence-Based Complementary and Alternative Medicine 2006, 3:441-445.
12. Downward J. PI 3-kinase, Akt and cell survival. Seminars in Cell & Developmental Biology 2004, 15:177-182.
13. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997, 275:661-665.
14. Eberhardt O., Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicology Letters 2003, 139:135-151.
15. Ferry P., Johnson M., Wallis P. Use of complementary therapies and non-prescribed medication in patients with Parkinson's disease. Postgraduate Medical Journal 2002, 78:612-614.
16. Fruman D.A., Meyers R.E., Cantley L.C. Phosphoinositide kinases. Annual Review of Biochemistry 1998, 67:481-507.
17. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., Hirsch E.C. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:2875-2880.
18. Hetman M., Kanning K., Cavanaugh J.E., Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. Journal of Biological Chemistry 1999, 274:22569-22580.
19. Hayley S., Crocker S.J., Smith P.D., Shree T., Jackson-Lewis V., Przedborski S., Mount M., Slack R., Anisman H., Park D.S. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Journal of Neuroscience 2004, 24:2045-2053.
20. Hetman M., Xia Z. Signaling pathways mediating anti-apoptotic action of neurotrophins. Acta Neurobiologiae Experimentalis (Wars) 2000, 60:531-545.
21. Iwasaki K., Maruyama M., Tomita N., Furukawa K., Nemoto M., Fujiwara H., Seki T., Fujii M., Kodama M., Arai H. Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. Journal of Clinical Psychiatry 2005, 66:1612-1613.
22. Iwasaki K., Satoh-Nakagawa T., Maruyama M., Monma Y., Nemoto M., Tomita N., Tanji H., Fujiwara H., Seki T., Fujii M., Arai H., Sasaki H. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. Journal of Clinical Psychiatry 2005, 66:248-252.
23. Jeon S., Kim Y.J., Kim S.T., Moon W., Chae Y., Kang M., Chung M.Y., Lee H., Hong M.S., Chung J.H., Joh T.H., Park H.J. Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model. Proteomics 2008, 8:4822-4832.
24. Kawakami Z., Kanno H., Ueki T., Terawaki K., Tabuchi M., Ikarashi Y., Kase Y. Neuroprotective effects of Yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cells. Neuroscience 2009, 159:1397-1407.
25. Kim K.-S., Sung G.-K., Moon B.-S. An experimental study on the antiepileptic effects of Ukgansan. Journal of Korean Internal Medicine 1998, 19:57-72.
26. Kim S.R., Lee T.Y., Kim M.S., Lee M.C., Chung S.J. Use of complementary and alternative medicine by Korean patients with Parkinson's disease. Clinical Neurology and Neurosurgery 2009, 111:156-160.
27. Krepinsky J.C., Li Y., Chang Y., Liu L., Peng F., Wu D., Tang D., Scholey J., Ingram A.J. Akt mediates mechanical strain-induced collagen production by mesangial cells. Journal of the American Society of Nephrology 2005, 16:1661-1672.
28. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. New England Journal of Medicine 1998, 339:1044-1053.
29. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. New England Journal of Medicine 1998, 339:1130-1143.
30. Lawlor B. Managing behavioural and psychological symptoms in dementia. British Journal of Psychiatry 2002, 181:463-465.
31. Lee J.G., Kay E.P. Common and distinct pathways for cellular activities in FGF-2 signaling induced by IL-1beta in corneal endothelial cells. Investigative Ophthalmology & Visual Science 2009, 50:2067-2076.
32. Lu J., Park C.S., Lee S.K., Shin D.W., Kang J.H. Leptin inhibits 1-methyl-4-phenylpyridinium-induced cell death in SH-SY5Y cells. Neuroscience Letters 2006, 407:240-243.
33. Miyazaki T., Bub J.D., Iwamoto Y. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt. Biochimica et Biophysica Acta 2008, 1782:593-604.
34. Mizukami K., Asada T., Kinoshita T., Tanaka K., Sonohara K., Nakai R., Yamaguchi K., Hanyu H., Kanaya K., Takao T., Okada M., Kudo S., Kotoku H., Iwakiri M., Kurita H., Miyamura T., Kawasaki Y., Omori K., Shiozaki K., Odawara T., Suzuki T., Yamada S., Nakamura Y., Toba K. A randomized cross-over study of a traditional Japanese medicine (kampo), Yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. International Journal of Neuropsychopharmacology 2009, 12:191-199.
35. Monji A., Takita M., Samejima T., Takaishi T., Hashimoto K., Matsunaga H., Oda M., Sumida Y., Mizoguchi Y., Kato T., Horikawa H., Kanba S. Effect of Yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. Progress in Neuropsychopharmacology & Biological Psychiatry 2009, 33:308-311.
36. Nakaso K., Ito S., Nakashima K. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neuroscience Letters 2008, 432:146-150.
37. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sciences 1985, 36:2503-2508.
38. Nicotra A., Parvez S. Apoptotic molecules and MPTP-induced cell death. Neurotoxicology and Teratology 2002, 24:599-605.
39. Niso-Santano M., Moran J.M., Garcia-Rubio L., Gomez-Martin A., Gonzalez-Polo R.A., Soler G., Fuentes J.M. Low concentrations of paraquat induces early activation of extracellular signal-regulated kinase 1/2, protein kinase B, and c-Jun N-terminal kinase 1/2 pathways: role of c-Jun N-terminal kinase in paraquat-induced cell death. Toxicological Sciences 2006, 92:507-515.
40. Quesada A., Lee B.Y., Micevych P.E. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Developmental Neurobiology 2008, 68:632-644.
41. Rozas G., Guerra M.J., Labandeira-Garcia J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Research. Brain Research Protocols 1997, 2:75-84.
42. Rozas G., Lopez-Martin E., Guerra M.J., Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of parkinsonism. Journal of Neuroscience Methods 1998, 83:165-175.
43. Stein R.C., Waterfield M.D. PI3-kinase inhibition: a target for drug development?. Molecular Medicine Today 2000, 6:347-357.
44. Tabuchi M., Yamaguchi T., Iizuka S., Imamura S., Ikarashi Y., Kase Y. Ameliorative effects of Yokukansan, a traditional Japanese medicine, on learning and non-cognitive disturbances in the Tg2576 mouse model of Alzheimer's disease. Journal of Ethnopharmacology 2009, 122:157-162.
45. Takeuchi H., Yanagida T., Inden M., Takata K., Kitamura Y., Yamakawa K., Sawada H., Izumi Y., Yamamoto N., Kihara T., Uemura K., Inoue H., Taniguchi T., Akaike A., Takahashi R., Shimohama S. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. Journal of Neuroscience Research 2009, 87:576-585.
46. Tateno M., Ukai W., Ono T., Saito S., Hashimoto E., Saito T. Neuroprotective effects of Yi-Gan San against beta amyloid-induced cytotoxicity on rat cortical neurons. Progress in Neuropsychopharmacology & Biological Psychiatry 2008, 32:1704-1707.
47. Timmons S., Coakley M.F., Moloney A.M., O'Neill C. Akt signal transduction dysfunction in Parkinson's disease. Neuroscience Letters 2009, 467:30-35.
48. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Journal of Neurochemistry 1993, 61:1191-1206.
49. Yokoyama H., Yano R., Aoki E., Kato H., Araki T. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. Metabolic Brain Disease 2008, 23:335-349.
50. Zigmond M.J., Stricker E.M. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. International Review of Neurobiology 1989, 31:1-79.